Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct;33(10):1863-1873.
doi: 10.1111/jdv.15782. Epub 2019 Jul 30.

Cutaneous candidiasis - an evidence-based review of topical and systemic treatments to inform clinical practice

E H Taudorf  1   2 , G B E Jemec  1   2 , R J Hay  3 , D M L Saunte  1   2
Affiliations
Review

Cutaneous candidiasis - an evidence-based review of topical and systemic treatments to inform clinical practice

E H Taudorf et al. J Eur Acad Dermatol Venereol. 2019 Oct.

Abstract

Cutaneous candidiasis is a common skin disease, and several treatments have been investigated within the last fifty years. Yet, systematic reviews are lacking, and evidence-based topical and systemic treatment strategies remain unclear. Thus, the aim of this review was to summarize efficacy and adverse effects of topical and oral therapies for cutaneous candidiasis in all age groups. Two individual researchers searched PubMed and EMBASE for 'cutaneous candidiasis' and 'cutaneous candidiasis treatment', 'intertrigo', 'diaper dermatitis' and 'cheilitis'. Searches were limited to 'English language', 'clinical trials' and 'human subjects', and prospective clinical trials published in abstracts or articles were included. In total, 149 studies were identified, of which 44 were eligible, comprising 41 studies of 19 topical therapies and four studies of three systemic therapies for cutaneous candidiasis. Topical therapies were investigated in infants, children, adolescents, adults and elderly, while studies of systemic therapies were limited to adolescents and adults. Clotrimazole, nystatin and miconazole were the most studied topical drugs and demonstrated similar efficacy with complete cure rates of 73%-100%. Single-drug therapy was as effective as combinations of antifungal, antibacterial and topical corticosteroid. Four studies investigated systemic therapy, and oral fluconazole demonstrated similar efficacy to oral ketoconazole and topical clotrimazole. Limitations to this review were mainly that heterogeneity of studies hindered meta-analyses. In conclusions, clotrimazole, nystatin and miconazole were the most studied topical drugs and demonstrated equal good efficacy and mild adverse effects similar to combinations of antifungal, antibacterial and topical corticosteroids. Oral fluconazole was as effective as topical clotrimazole and is the only commercially available evidence-based option for systemic treatment of cutaneous candidiasis.

PubMed Disclaimer

References

    1. Sei Y. 2011 epidemiological survey of dermatomycoses in Japan. Med Mycol J 2015; 56: J129-J135.
    1. Peñate Y, Guillermo N, Melwani P et al. Dermatologists in hospital wards: an 8-year study of dermatology consultations. Dermatology 2009; 219: 225-231.
    1. Cutaneous candidiasis [WWW Document]. Medscape. URL https://emedicine.medscape.com
    1. Del Rosso JQ, Kircik LH. Optimizing topical antifungal therapy for superficial cutaneous fungal infections: focus on topical naftifine for cutaneous dermatophytosis. J Drugs Dermatol 2013; 12: s165-s171.
    1. Nenoff P, Krüger C, Schaller J et al. Mykologie ein update teil 2: dermatomykosen: klinisches bild und diagnostik. J Dtsch Dermatol Ges 2014; 12: 749-779.

MeSH terms

LinkOut - more resources